Key Highlights

  • Shares rose 12.52%, or USD 0.8657, to USD 7.78 in regular trading on November 3, 2026.
  • The base purchase price is USD 125 million, with up to USD 45 million more tied to Revenue and EBITDA milestones.
  • Financing includes two USD 50 million term loans and a USD 25 million convertible note, all from the seller.
  • The combined Business is projected to generate USD 400 million to USD 450 million in annual revenue.
  • The company withdrew its 2026 guidance because of expected transaction and financing costs.

What Moved the Shares Today (up USD 0.8657, 12.52%)

Rockwell Medical (NASDAQ:RMTI) was up 12.52% to USD 7.78 in regular trading on November 3, 2026, a gain of USD 0.8657 from the November 2, 2026 close, which implies a prior close near USD 6.91 (calculated). The catalyst was a company announcement the same day of a definitive agreement to acquire the hemodialysis business of Vantive.

The screen showed a Market Capitalisation of about USD 31.34 million, so the USD 125 million base price is roughly four times the company's Equity value (calculated).

The Vantive Agreement in Detail

According to a press release dated November 3, 2026, Rockwell will acquire hemodialysis concentrates, monitors and water treatment systems, plus related consumables and technical services. A Manufacturing campus in Medolla, Italy transfers on completion, while the dialyzer portfolio, including the Theranova dialyzer, stays with the seller.

The consideration is USD 125 million, subject to customary adjustments, plus up to USD 45 million of contingent payments based on revenue and EBITDA milestones. Financing comes from two USD 50 million term loans and a USD 25 million convertible note, with the note's conversion price set at a 100% premium to the 15-day Volume weighted average price.

The company estimates the combined business would generate USD 400 million to USD 450 million of annual revenue. Closing is expected in mid-2027, subject to regulatory approvals and other conditions.

Business Background and Recent Results

Rockwell, based in Wixom, Michigan, develops, manufactures and distributes hemodialysis products, mainly concentrates, to dialysis providers worldwide. For the quarter ended June 30, 2026, net sales were USD 17.8 million, up 11% from USD 16.1 million, and gross Margin rose to 18% from 16%.

The net loss narrowed to USD 1.2 million, and Operating Cash Flow was positive at USD 2.1 million. Before the deal the company had guided to 2026 net sales of USD 70 million to USD 75 million, which it has now withdrawn. Third quarter results are scheduled for November 12, 2026.

Balance Sheet and Risks

Cash, equivalents and investments were USD 24.8 million at June 30, 2026. Seller financing of USD 125 million in loans and notes would add substantial Leverage to a company of this size, and the convertible note could dilute holders if converted.

A 1-for-10 Reverse Stock Split took effect on July 1, 2026, and the company regained Nasdaq minimum bid compliance on July 20, 2026. The acquired business is much larger than Rockwell, so integration of the Italian plant and new product lines carries execution risk, and the deal may not close on schedule.

What to Watch Next

Key items include regulatory approvals, the milestone definitions for the contingent payments, and the third quarter results on November 12, 2026, which may show how the company plans to carry the new debt. Updated guidance after closing is another point to follow.